| Evaluation of p53 and Bax Expression as Prognostic Markers in Invasive Cervical Carcinoma Stage IIB Patients Treated with Radiation Therapy |
| Sukjin Choi, Hunjung Kim, Eunseop Song, Changyoung Kim, Meejo Lee, Woochul Kim, John J K Loh |
1Departments of Radiation Oncology, Inha University Medical College, Incheon, Korea.
2Departments of Pathology, Inha University Medical College, Incheon, Korea.
3Departments of Obstetrics and Gynecology, Inha University Medical College, Incheon, Korea. songsong2000@hotmail.com
4Department of Obstetrics and Gynecology, Sam Hospital, Anyang, Korea. |
|
|
|
|
|
| ABSTRACT |
PURPOSE:
The objective of our study was to evaluate the immunohistochemical expression of p53 and bax proteins as prognostic markers in FIGO stage IIb invasive squamous cell carcinoma of the uterine cervix.
MATERIALS AND METHODS:
Sixty-five cases of squamous cell carcinoma of the cervix (stage IIb) that were diagnosed from October 1996 to December 2003 were analyzed retrospectively for the bax and p53 expression. These expressions were determined immunohistochemically and they were correlated to the patients' overall survival and disease-free survival.
RESULTS:
The overall 5-year survival (OS) rate and the disease-free survival (DFS) rate were 65.1% and 62.9%, respectively. p53 and bax immunoreactivity was seen in 26.2% and 52.3% of cases, respectively, with variable levels of expression. On the univariate analysis, only p53 positivity correlated with poor survival in DFS (log-rank test p=0.027), but this significance was not maintained on multivariated analysis by Cox's regression. The nine cases with the immunophenotype p53+/bax- had the poorest survival.
CONCLUSION:
Neither p53 nor bax expression are independent predictors of the prognosis for stage IIb cervical squamous cancers. Evaluation of p53 and bax co-expression may affect the clinical outcome and further investigation is needed. |
| Key Words:
p53, Bax, Cervical carcinoma, Prognosis |
|
PDF Links
Full text via DOI 
Download Citation 
